Persistent cyanosis in the newborn – diagnostic approach (hyperoxia test)
Cardiac vs respiratory cyanosis · Paediatric
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Persistent central cyanosis in a newborn requires rapid differentiation of cardiac from respiratory/other causes; the hyperoxia (nitrogen washout) test helps distinguish fixed intracardiac shunting from reversible pulmonary causes. This protocol covers the structured diagnostic work-up while stabilising the infant.
Red flags
- Cyanosis unresponsive to 100% oxygen
- Differential pre-/post-ductal saturations
- Shock or collapse
- Weak femoral pulses or a pathological murmur
- Low SpO2 with a paradoxically normal PaO2 (methaemoglobinaemia)
Assessment
Differential diagnosis
- Cyanotic congenital heart disease (e.g. transposition, tetralogy, TAPVC)
- Persistent pulmonary hypertension of the newborn
- Parenchymal lung disease (RDS/MAS/pneumonia)
- Airway obstruction (choanal atresia, Pierre Robin)
- Sepsis
- Methaemoglobinaemia or polycythaemia
Investigations
- Pre- and post-ductal SpO2 and four-limb assessment
- Arterial blood gas in room air and in high-flow 100% oxygen (hyperoxia test)
- Chest radiograph
- ECG
- Echocardiography (definitive for structural heart disease and PPHN)
- Full blood count, blood glucose, blood culture and consider methaemoglobin level
Management
- Confirm true central cyanosis (not peripheral/acrocyanosis) and check SpO2 pre- and post-ductally.
- Stabilise airway, breathing and circulation; apply monitoring and obtain IV access.
- Perform the hyperoxia test: measure a baseline pre-ductal (right radial) arterial PaO2, then deliver 100% oxygen for ~10 minutes and repeat the arterial PaO2.
- Interpret: a PaO2 that rises to >150–200 mmHg suggests a respiratory cause; a PaO2 that stays low (<100–150 mmHg) despite 100% O2 suggests fixed cardiac shunting (cyanotic CHD) or severe PPHN.
- Use SpO2 cautiously – arterial PaO2 is more discriminating because saturation can plateau near 100% and mask the difference.
- Look for a pre-/post-ductal difference suggesting duct-dependent flow or PPHN.
- If cyanotic duct-dependent CHD is suspected, start prostaglandin without waiting for definitive imaging.
- Obtain urgent echocardiography to define the diagnosis.
- Treat reversible causes in parallel (sepsis, lung disease, airway obstruction).
- In suspected methaemoglobinaemia (low SpO2 with normal PaO2, chocolate-brown blood), consider methylthioninium chloride.
- Avoid high FiO2 harm in preterm/PPHN once a cardiac cause is identified.
- Refer to cardiology/tertiary centre as dictated by the diagnosis.
Drugs & doses
Prostaglandin E1 (alprostadil) 5–20 nanogram/kg/min IV to maintain ductal patency for suspected duct-dependent cyanotic CHD
100% oxygen via headbox/high-flow for the hyperoxia test
Inhaled nitric oxide 20 ppm for confirmed PPHN
Methylthioninium chloride (methylene blue) 1–2 mg/kg IV over 5 min for methaemoglobinaemia
0.9% sodium chloride 10 mL/kg IV for shock
Disposition
NICU with cardiology access and echocardiography; start prostaglandin for suspected duct-dependent lesions; transfer to a cardiac centre once a cardiac cause is confirmed.
Complications & pitfalls
- Delayed diagnosis of duct-dependent CHD with collapse
- Hyperoxic injury if high FiO2 continued inappropriately
- Apnoea from prostaglandin
- Progressive hypoxaemia and acidosis
- Multi-organ injury
Exam pearls
- A failed hyperoxia test (PaO2 remaining low) points to cardiac disease or severe PPHN.
- Use arterial PaO2, not just SpO2, to interpret the hyperoxia test.
- When in doubt with a sick cyanosed baby, start prostaglandin – it is reversible and potentially life-saving.
- Normal PaO2 with low SpO2 and brown blood means methaemoglobinaemia.
- Echocardiography is the definitive test – arrange it urgently.
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.